Mabwell (Shanghai) Bioscience Co., Ltd. (HKG:2493)

Market Cap	13.58B -35.8%
Revenue (ttm)	1.01B +371.4%
Net Income	-1.08B
EPS	-2.67
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	53,400
Open	21.74
Previous Close	20.34
Day's Range	19.80 - 21.74
52-Week Range	19.80 - 31.46
Beta	0.52
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 29, 2026

About HKG:2493

Mabwell (Shanghai) Bioscience Co., Ltd., a biopharmaceutical company, engages in the research and development, manufacture, and commercialization of biological products for oncology, immunology, bone disorders, ophthalmology, hematology, and infectious diseases in China and internationally. The company offers MAIWEIJIAN for the treatment of giant cell tumor of bone; MALISHU for the treatment of postmenopausal women with osteoporosis; MAILISHENG, an albipagrastim alfa injection; and JUNMAIKANG, an autoimmune Adalimumab injection. It also provide...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2017
• Employees: 1,356
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2493

Financial Performance

In 2025, HKG:2493's revenue was 662.52 million, an increase of 231.62% compared to the previous year's 199.78 million. Losses were -969.33 million, -7.14% less than in 2024.

Financial numbers in CNY

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 7, 2026

Data Sources Report a data error